AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Kalaris Therapeutics Inc
Video analysis: KLRS
All videosNo video analysis for this stock yet. Request one from our team.
News: KLRS
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the second quarter ended June 30, 2026 and provided business updates.
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report)'s stock price rose 15.4% during mid-day trading on Monday. The company traded as high as $4.09 and last traded at $4.05. Approximately 155,903 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 653,556 shares. The stock had previously closed
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir) holders who owned shares before November 7, 2024.
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in treatment naïve nAMD patients BERKELEY HEIGHTS, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Liisa Bayko, MBA, as Chief Financial Officer.
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts
Kalaris Appoints Laurie Keating to Board of Directors
Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of Phase 1a data at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting.
